CSF1R inhibitors Pexidartinib and Cabiralizumab have been tested in clinical trials with standard therapies or immune checkpoint blockade in advanced pancreatic cancer patients (NCT02777710, NCT03336216, NCT02526017). The gene discussed is CSF1R; the disease is familial pancreatic carcinoma.